Welcome to our dedicated page for BlackRock Tech and Private Equity Term news (Ticker: BTX), a resource for investors and traders seeking the latest updates and insights on BlackRock Tech and Private Equity Term stock.
BlackRock Technology and Private Equity Term Trust (BTX) generates news and disclosures that focus on its role as a BlackRock-managed closed-end term trust with an equity investment strategy. Coverage often centers on the Fund’s managed distribution plan, tender offers for its common shares, and communications from its Board of Trustees regarding distribution policy and capital management.
Recent news has highlighted decisions by the Board of Trustees to update BTX’s managed distribution plan, including a shift from a floating rate distribution to a level rate distribution at a stated monthly rate. These announcements explain the rationale for the changes, such as enhancing distribution stability, maintaining a competitive distribution rate and managing the mix of public and private investments. News items also provide estimated allocations of distributions among net income, capital gains and return of capital, along with explanations of what return of capital means for shareholders and net asset value.
Another key theme in BTX news is corporate actions involving its capital structure. The Fund has announced the commencement, expiration, preliminary results and final results of a tender offer to repurchase up to 50% of its outstanding common shares at a price tied to net asset value. These releases describe the tender offer terms, the number of shares offered and tendered, and the pricing mechanism, while directing investors to the formal tender offer documents filed with the SEC.
Investors following BTX news can expect updates on distribution policies, estimates of distribution sources, tender offer activity, and references to where to find official reports and regulatory filings. Monitoring these announcements helps readers understand how the Fund’s Board manages distributions and capital actions within the framework of its investment objective and regulatory requirements.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced restricted stock unit grants for Sandra M. Gurrola (35,000 shares) and Kevin A. D’Amour (70,290 shares) along with a non-qualified stock option covering 140,580 shares. These awards vest over four years with specific conditions tied to employment. This move is part of their 2021 Inducement Stock Incentive Plan, designed to attract talent. The company focuses on cytokine and gene editing therapies for cancer treatment, with its lead program, IRX-2, showing promising results in head and neck cancer clinical trials.
Brooklyn ImmunoTherapeutics (BTX) has signed a non-binding letter of intent to acquire Novellus Therapeutics for approximately $125 million, comprising $17.4 million in cash and $107.6 million in BTX stock. The acquisition aims to enhance Brooklyn's gene editing and cell therapy capabilities and is expected to close by July 15, 2021. The completion depends on due diligence and various approvals, with Brooklyn having over $43 million in cash available. This acquisition aligns with Brooklyn's strategy to lead in next-generation stem cell therapy.
BROOKLYN, N.Y., June 09, 2021 - Brooklyn ImmunoTherapeutics (BTX) announced its addition to the Russell 3000 Index, effective June 28, 2021. This recognition enhances the visibility of its innovative therapies targeting cancer, blood disorders, and monogenic disorders. With approximately $10.6 trillion in assets benchmarked against Russell’s U.S. Indexes, membership opens new opportunities for investment. The company’s lead program, IRX-2, has shown promising results in Phase 2A trials for head and neck cancer, indicating a potential overall survival benefit.
BROOKLYN, N.Y., June 08, 2021 – Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced the appointment of Dr. Kevin A. D’Amour as Chief Scientific Officer. Dr. D’Amour, previously Chief Scientific Officer at ViaCyte, brings over 100 patents and extensive experience in cell and gene therapy. CEO Howard J. Federoff highlighted Dr. D’Amour's expertise as pivotal for Brooklyn's pioneering work in innovative cancer treatments. Brooklyn is advancing therapies for cancer and blood disorders, utilizing exclusive technologies from Factor Bioscience and Novellus, with its lead program studying IRX-2 in head and neck cancer.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) has established a new research and development center in Cambridge, Massachusetts, co-locating with Factor Bioscience and Novellus Therapeutics. This facility will focus on mRNA-based gene editing and cellular therapies for cancer and rare blood disorders, leveraging exclusive licenses from both companies. Key technologies include mRNA cell reprogramming, mRNA-based gene editing, and a nanolipid delivery system. Brooklyn's leading program is IRX-2 for head and neck cancer, which showed promising overall survival benefits in clinical trials.
BROOKLYN ImmunoTherapeutics (NYSE American: BTX) updates investors on its innovative treatments targeting cancer and blood disorders. Key highlights include the advancement of IRX-2, a Phase 2 asset for head and neck cancer, which has shown promising overall survival benefits. The company also announced a new license for mRNA cell reprogramming technology aimed at enhancing treatment options for various tumors and genetic disorders. Brooklyn aims to solidify its financial position while exploring new therapeutic avenues.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) has successfully completed a $20 million financing aimed at advancing its mRNA gene editing and cell therapies technology, licensed from Factor Biosciences and Novellus Therapeutics. The funds will facilitate the translation of this technology into clinical programs targeting orphan diseases, such as sickle cell anemia and familial amyloidosis. The licensed platform includes novel mRNA-based methods for gene editing and cellular reprogramming, enhancing therapeutic efficiency while minimizing off-target effects. Brooklyn's leading program is IRX-2, currently undergoing Phase 2A trials for head and neck cancer.
Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Dr. Michael Andreeff to its Scientific Advisory Board, effective May 21, 2021. Dr. Andreeff, a leading expert in leukemia treatment and molecular hematology at MD Anderson Cancer Center, brings extensive experience in developing therapies for blood disorders. His expertise is anticipated to enhance Brooklyn's gene editing and cell therapy initiatives, especially following the company’s recent licensing agreement for gene editing technology. Brooklyn is currently advancing its IRX-2 program for head and neck cancer, demonstrating promise in clinical trials.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced a conference call scheduled for May 25, 2021, at 4:30 p.m. ET. Participants must pre-register to receive the dial-in information. The call will address the company's exploration of cytokine and gene editing therapies for cancer and blood disorders. The lead program, IRX-2, is undergoing a Phase 2A trial, showing promising survival benefits for head and neck cancer patients. The company aims to advance treatments through newly acquired gene editing licenses.
Brooklyn ImmunoTherapeutics (BTX) has announced a publication in Breast Cancer Research showcasing the effectiveness of multiplex immunofluorescence (mIF) in assessing immunological activity of IRX-2 in early-stage breast cancer. This methodology offers improved estimates of treatment-related effects compared to conventional methods. IRX-2, a cytokine-based therapy, has shown promise in increasing immune cell infiltration, particularly when combined with PD-L1-targeted therapies. Brooklyn has launched a Phase 2 trial for IRX-2 in triple-negative breast cancer, with approximately 30 patients expected to participate.